<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03589196</url>
  </required_header>
  <id_info>
    <org_study_id>MS/18.02.30</org_study_id>
    <nct_id>NCT03589196</nct_id>
  </id_info>
  <brief_title>Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate: A RCT</brief_title>
  <acronym>EPPROSTATECT</acronym>
  <official_title>Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate For Management Of Benign Prostatic Enlargement: An Objective Evaluation Through a Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate and compare the outcome and coast of ejaculation sparing management of BPH using
      3 different techniques: PVP, PKVP and TURP. Ejaculation sparing TURP group is considered the
      standard control group. Evaluation will be carried out through a prospective randomized
      powered trial
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">March 10, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>estimate and compare the ejaculation preservation effect of the 3 techniques (PKVP, PVP and TURP).</measure>
    <time_frame>1 years</time_frame>
    <description>assessed by Male Sexual Health Questionnaire (MSHQ)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in flow rate</measure>
    <time_frame>1 years</time_frame>
    <description>measured by uroflowmetery in ml/sec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complication</measure>
    <time_frame>1 year</time_frame>
    <description>measured by Clavien-Dindo Classification scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in patients' symptoms.</measure>
    <time_frame>1 year</time_frame>
    <description>measured by International Prostate Symptom Score (I-PSS)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Ejaculation Abnormal</condition>
  <condition>BPH With Urinary Obstruction</condition>
  <condition>Prostatic Hyperplasia</condition>
  <condition>Prostate Disease</condition>
  <condition>Prostate Obstruction</condition>
  <arm_group>
    <arm_group_label>Photoselective Vaporization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasma Kinetic Vaporization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Transurethral Resection Of The Prostate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ejaculation Preserving Photoselective Vaporization</intervention_name>
    <description>Ejaculation Preserving Photoselective Vaporization</description>
    <arm_group_label>Photoselective Vaporization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ejaculation Preserving Plasma Kinetic Vaporization</intervention_name>
    <description>Ejaculation Preserving Plasma Kinetic Vaporization</description>
    <arm_group_label>Plasma Kinetic Vaporization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ejaculation Preserving Transurethral Resection Of The Prostate</intervention_name>
    <description>Ejaculation Preserving Transurethral Resection Of The Prostate</description>
    <arm_group_label>Transurethral Resection Of The Prostate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age &gt;50 years 2. Prostate volume (measured by TRUS): 30-80 gm 3. International
             prostate symptom score (IPSS )&gt;15 and quality of life score (QOL)&lt; 3.

             4. Maximum flow rate of uroflometry &lt;10 ml/second 5. Patients with active sexual life
             (or interested) and having the ability to ejaculate and desire to preserve
             ejaculation.

             6. Failure or intolerance to medical treatment, recurrent urinary infection, urine
             retention, significant hematuria or deterioration of the upper urinary tract function
             secondary to BOO.

        Exclusion Criteria:

          1. Bleeding disorders and patients on anticoagulant treatment

          2. Histologically proved cancer prostate

          3. Neurogenic voiding dysfunction

          4. Lower urinary tract malignancy

          5. Preoperative ejaculation or sexual dysfunction

          6. Presence of stricture urethra

          7. Unfit for spinal anathesia -
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Urology &amp; Nephrology Center</name>
      <address>
        <city>Mansourah</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>May 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>July 4, 2018</last_update_submitted>
  <last_update_submitted_qc>July 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Prostatic Diseases</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

